Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
Biocon Limited
BIOCONBiocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India. Address: 20th KM Hosur Road, Bengaluru, India, 560100
Analytics
Zielpreis von Wall Street
27 962.48 INRKGV
26.7304Dividendenrendite
0.15 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen BIOCON
Dividenden-Analyse BIOCON
Dividendenwachstum über 5 Jahre
200 %Kontinuierliches Wachstum
1 JahrAusschüttungsquote 5-Jahres-Durchschnitt
18 %Verlauf der Dividende BIOCON
Bewertung der Aktie BIOCON
Finanzen BIOCON
Ergebnisse | 2019 | Dynamik |